{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:13:53Z","timestamp":1789010033754,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial assessing lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) in the first prospective comprehensive analysis of different techniques, molecular markers, and tissues (peripheral blood [PB] and bone marrow [BM]), taken at well-defined time points. Among the 300 patients enrolled, a molecular marker was identified in 250 (83%), allowing us to analyze 234 patients and 4351 analytical findings from 10 time points. ASCT induced high rates of molecular remission (91% in PB and 83% in BM, by quantitative real-time polymerase chain reaction [RQ-PCR]). Nevertheless, the number of patients with persistent clinical and molecular remission decreased over time in both arms (up to 30% after 36 months). MRD predicted early progression and long-term outcome, particularly from 6 months after ASCT (6-month time to progression [TTP] hazard ratio [HR], 3.83; P &amp;lt; .001). In single-timepoint analysis, BM outperformed PB, and RQ-PCR was more reliable, while nested PCR appeared applicable to a larger number of patients (234 vs 176). To improve MRD performance, we developed a time-varying kinetic model based on regularly updated MRD results and the MIPI (Mantle Cell Lymphoma International Prognostic Index), showing an area under the ROC (Receiver Operating Characteristic) curve (AUROC) of up to 0.87 using BM. Most notably, PB reached an AUROC of up to 0.81; with kinetic analysis, it was comparable to BM in performance. MRD is a powerful predictor over the entire natural history of MCL and is suitable for models with a continuous adaptation of patient risk. The study can be found in EudraCT N. 2009-012807-25 (https:\/\/eudract.ema.europa.eu\/).<\/jats:p>","DOI":"10.1182\/blood.2021014270","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T15:52:50Z","timestamp":1655999570000},"page":"1378-1389","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"first","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"},{"name":"2AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"},{"name":"3Hematology Division, AO S.Croce e Carle, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-1206","authenticated-orcid":false,"given":"Daniela","family":"Drandi","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-5917","authenticated-orcid":false,"given":"Gian Maria","family":"Zaccaria","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"},{"name":"4Hematology and Cell Therapy Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Alessandria","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-1563","authenticated-orcid":false,"given":"Marco","family":"Ghislieri","sequence":"additional","affiliation":[{"name":"5PoliToBIOMed Lab, Politecnico di Torino, Torino, Italy;"},{"name":"6Department of Electronics and Telecommunications, Politecnico di Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-9603","authenticated-orcid":false,"given":"Martina","family":"Ferrante","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-2805","authenticated-orcid":false,"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[{"name":"7Unit of Cancer Epidemiology, CPO, AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mantoan","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"De Luca","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-851X","authenticated-orcid":false,"given":"Piero Maria","family":"Stefani","sequence":"additional","affiliation":[{"name":"8Hematology Unit, General Hospital Ca' Foncello, Treviso, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benedetti","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Casaroli","sequence":"additional","affiliation":[{"name":"10Hematology Unit, Ospedale San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[{"name":"3Hematology Division, AO S.Croce e Carle, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"12Hematology, Card. G. Panico Hospital, Tricase, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1017-6961","authenticated-orcid":false,"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[{"name":"13Santa Chiara University Hospital, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Re","sequence":"additional","affiliation":[{"name":"14Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-7197","authenticated-orcid":false,"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[{"name":"15Hematology Unit, Universit\u00e0 Cattolica S.Cuore; Roma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1032","authenticated-orcid":false,"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[{"name":"17Hematology, Casa Sollievo della Sofferenza IRCCS Hospital, San Giovanni Rotondo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[{"name":"18Department of Hematology, San Martino Hospital and University, Genova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"19Department of Hematology, A.O. Santa Maria Terni, University of Perugia, Perugia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cortelazzo","sequence":"additional","affiliation":[{"name":"20Oncology Unit, Clinica Humanitas Gavazzeni, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2022092215284673500_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol."},{"issue":"10044","key":"2022092215284673500_B2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet."},{"issue":"13","key":"2022092215284673500_B3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022092215284673500_B4","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial","volume":"8","author":"Ladetto","year":"2021","journal-title":"Lancet Haematol."},{"key":"2022092215284673500_B5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/aol-2018-mcl-010","article-title":"Tailored treatment in mantle cell lymphoma","volume":"4","author":"Ferrero","year":"2020","journal-title":"Ann Lymphoma."},{"issue":"16","key":"2022092215284673500_B6","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood."},{"issue":"3","key":"2022092215284673500_B7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022092215284673500_B8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica."},{"key":"2022092215284673500_B9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-140457","article-title":"Predictive power of early, sequential mrd monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; final results from the lyma-MRD project, conducted on behalf of the lysa group","volume":"136","author":"Callanan","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2022092215284673500_B10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.leu.2404535","article-title":"Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia."},{"issue":"2","key":"2022092215284673500_B11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17519","article-title":"Application of the Euro clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial","volume":"194","author":"Genuardi","year":"2021","journal-title":"Br J Haematol."},{"key":"2022092215284673500_B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136565","article-title":"Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: phase II, investigator-initiated, single-center study","volume":"136","author":"Epstein-Peterson","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022092215284673500_B13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ijlh.12766","article-title":"Ficoll-hypaque separation vs whole blood lysis: comparison of efficiency and impact on minimal residual disease analysis","volume":"40","author":"Genuardi","year":"2018","journal-title":"Int J Lab Hematol."},{"issue":"2","key":"2022092215284673500_B14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10428194.2014.914199","article-title":"Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network","volume":"57","author":"Mannu","year":"2016","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"2022092215284673500_B15","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"2022092215284673500_B16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","article-title":"A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors","volume":"11","author":"Voena","year":"1997","journal-title":"Leukemia."},{"issue":"7","key":"2022092215284673500_B17","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood."},{"issue":"3","key":"2022092215284673500_B18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","article-title":"Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma","volume":"6","author":"Ladetto","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022092215284673500_B19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia."},{"issue":"3","key":"2022092215284673500_B20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J Mol Biol."},{"key":"2022092215284673500_B21","doi-asserted-by":"crossref","first-page":"i379","DOI":"10.1093\/bioinformatics\/bth945","article-title":"IMGT\/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs","volume":"20","author":"Yousfi Monod","year":"2004","journal-title":"Bioinformatics."},{"key":"2022092215284673500_B22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-9151-8_9","article-title":"MRD detection in B-Cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR","volume":"1956","author":"Pott","year":"2019","journal-title":"Methods Mol Biol."},{"issue":"5","key":"2022092215284673500_B23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"issue":"2","key":"2022092215284673500_B24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1536867X0900900206","article-title":"Further development of flexible parametric models for survival analysis","volume":"9","author":"Lambert","year":"2009","journal-title":"Stata J."},{"issue":"1","key":"2022092215284673500_B25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics."},{"key":"2022092215284673500_B26","volume-title":"Package \u2018risksetROC\u2019.","author":"Heagerty","year":"2012"},{"key":"2022092215284673500_B27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","article-title":"MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR","volume":"538","author":"van der Velden","year":"2009","journal-title":"Methods Mol Biol."},{"issue":"5","key":"2022092215284673500_B28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hon.2550","article-title":"Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance","volume":"36","author":"Klener","year":"2018","journal-title":"Hematol Oncol."},{"issue":"11","key":"2022092215284673500_B29","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(20)30291-X","article-title":"Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group","volume":"7","author":"Le Gouill","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"2022092215284673500_B30","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/HS9.0000000000000347","article-title":"Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network","volume":"4","author":"Drandi","year":"2020","journal-title":"HemaSphere."},{"issue":"3","key":"2022092215284673500_B31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/hon.2864","article-title":"Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma","volume":"39","author":"Genuardi","year":"2021","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022092215284673500_B32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"23","key":"2022092215284673500_B33","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2022092215284673500_B34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol."},{"issue":"26","key":"2022092215284673500_B35","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood."},{"key":"2022092215284673500_B36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2021-145288","article-title":"Impact of maintenance arm on prognostic value of MRD after induction treatment in\u00a0MCL R2 elderly trial, a mantle cell lymphoma network study","volume":"138","author":"Delfau","year":"2021","journal-title":"Blood."},{"key":"2022092215284673500_B37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134875","article-title":"Pharmacogenomics drives lenalidomide efficacy and MRD kinetics in mantle cell lymphoma after autologous transplantation: results from the MCL0208 multicenter, phase III, randomized clinical trial from the Fondazione Italiana Linfomi (FIL)","volume":"136","author":"Ferrero","year":"2020","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/12\/1378\/1921368\/bloodbld2021014270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/12\/1378\/1921368\/bloodbld2021014270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:44:40Z","timestamp":1663847080000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/12\/1378\/485688\/Punctual-and-kinetic-MRD-analysis-from-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014270","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}